https://bioutah.org/lumea-named-best-new-biopsy-technology-solution-in-2026-medtech-breakthrough-awards/2026-05-22T03:10:27ZBioUtahenLumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards2026-05-21T15:04:27ZBloghttps://bioutah.org/co-diagnostics-develops-ebola-assay-strategy-following-recent-global-outbreak-alert/2026-05-22T03:09:27ZBioUtahenCo-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert2026-05-21T15:02:55ZBloghttps://bioutah.org/bluewind-medical-secures-47-8-million-financing-to-accelerate-commercialization-of-revi-system/2026-05-22T03:08:52ZBioUtahenBlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System2026-05-21T15:01:43ZBloghttps://bioutah.org/photopharmics-announces-last-patient-last-visit-in-pivotal-phase-3-light-for-pd-clinical-trial-company-to-present-topline-data-at-world-parkinson-congress/2026-05-22T03:01:21ZBioUtahenPhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress2026-05-21T15:00:34ZBlog